tetano
Editor, Senior Moderator
Vaccine
. 2022 Nov 15;40(48):6971-6978.
doi: 10.1016/j.vaccine.2022.10.042. Epub 2022 Oct 25.
Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients
Anand V Kulkarni[SUP] 1 [/SUP], Shashidhar Jaggaiahgari[SUP] 2 [/SUP], Sowmya Iyengar[SUP] 3 [/SUP], Venu Simhadri[SUP] 2 [/SUP], Deepika Gujjarlapudi[SUP] 4 [/SUP], Hardik Rugwani[SUP] 3 [/SUP], Venkata Krishna Vemula[SUP] 2 [/SUP], Baqar Ali Gora[SUP] 3 [/SUP], Sameer Shaik[SUP] 3 [/SUP], Mithun Sharma[SUP] 3 [/SUP], Mitnal Sasikala[SUP] 2 [/SUP], Nagaraja Rao Padaki[SUP] 3 [/SUP], K Rajender Reddy[SUP] 5 [/SUP], Duvvur Nageshwar Reddy[SUP] 3 [/SUP]
Affiliations
Abstract
Background and aims: Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs.
Methods: In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response.
Results: Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response.
Conclusion: Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines.
Keywords: Antibody formation; COVID-19 vaccines; Cellular immunity; Humoral immunity; Liver cirrhosis.
. 2022 Nov 15;40(48):6971-6978.
doi: 10.1016/j.vaccine.2022.10.042. Epub 2022 Oct 25.
Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients
Anand V Kulkarni[SUP] 1 [/SUP], Shashidhar Jaggaiahgari[SUP] 2 [/SUP], Sowmya Iyengar[SUP] 3 [/SUP], Venu Simhadri[SUP] 2 [/SUP], Deepika Gujjarlapudi[SUP] 4 [/SUP], Hardik Rugwani[SUP] 3 [/SUP], Venkata Krishna Vemula[SUP] 2 [/SUP], Baqar Ali Gora[SUP] 3 [/SUP], Sameer Shaik[SUP] 3 [/SUP], Mithun Sharma[SUP] 3 [/SUP], Mitnal Sasikala[SUP] 2 [/SUP], Nagaraja Rao Padaki[SUP] 3 [/SUP], K Rajender Reddy[SUP] 5 [/SUP], Duvvur Nageshwar Reddy[SUP] 3 [/SUP]
Affiliations
- PMID: 36374707
- DOI: 10.1016/j.vaccine.2022.10.042
Abstract
Background and aims: Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs.
Methods: In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response.
Results: Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response.
Conclusion: Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines.
Keywords: Antibody formation; COVID-19 vaccines; Cellular immunity; Humoral immunity; Liver cirrhosis.